Subscribe to RSS
DOI: 10.1055/a-2497-6568
Presumed Ectopic Trilateral Retinoblastoma: Case Report
Vermutliches ektopisches trilaterales Retinoblastom: über einen Fall
Introduction
Retinoblastoma (rb) is the most frequent intraocular tumor, occurring in 1 : 17 000 live births and accounting for 6% of all pediatric cancers under the age of 5 [1]. The disease can affect one or both eyes and is caused by a somatic or a germline mutation in the RB1 gene, a tumor suppressor gene located on the long arm of chromosome 13 (13q14) [1]. Children with heritable forms have a 3.5% risk of developing an intracranial midline primitive neuroectodermal tumor, usually located in the pineal gland (73 – 83% of cases) [2] – [4] or the suprasellar/parasellar region (11 – 22% of cases) [2], [4], [5], a condition known as trilateral retinoblastoma (Trb). Unusual locations with proven histopathology such as the third or fourth ventricle or the cerebellum (1%) [3], [5] have also been reported in isolated cases. Magnetic resonance imaging (1.5 or 3 Tesla MRI) is usually recommended for all rb cases at baseline, with a minimum annual examination for germline carriers until 3 to 5 years of age for the early detection of metachronous asymptomatic Trb. Carriers of a germline RB1 mutation are also at a lifetime risk of developing various types of secondary primary neoplasms (SPNs), especially if treated with external beam irradiation [1].
Management and outcome of rb patients depend greatly on the disease extent at presentation and access to a specialized center for ocular oncology. In high-income countries, where metastatic disease at presentation is rare, rb has 5-year disease-free survival rates of 97 – 99% [1]. Treatment of intraocular disease includes chemotherapy (intra-arterial, intravenous, and/or intraocular), focal treatments such as thermotherapy or cryotherapy, plaque brachytherapy, and/or enucleation. Despite progress made over the last decades, the outcome of metastatic disease, especially in cases of central nervous system (CNS) involvement, remains poor [1].
Herein, we report an atypical case of optic nerve sheath lesion in a child with bilateral rb, presumed to be an ectopic Trb, and discuss the differential diagnosis. Informed consent for publication was obtained from the patientʼs legal guardian.
Publication History
Received: 27 October 2024
Accepted: 04 December 2024
Article published online:
05 March 2025
© 2025. Thieme. All rights reserved.
Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
-
References
- 1 Munier FL, Beck-Popovic M, Chantada GL. et al. Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. “Alive, with good vision and no comorbidity”. Prog Retin Eye Res 2019; 73: 100764
- 2 de Jong MC, Kors WA, Moll AC. et al. Screening for Pineal Trilateral Retinoblastoma Revisited: A Meta-analysis. Ophthalmology 2020; 127: 601-607
- 3 Yamanaka R, Hayano A, Takashima Y. Trilateral retinoblastoma: A systematic review of 211 cases. Neurosurg Rev 2019; 42: 39-48
- 4 Paulino AC. Trilateral retinoblastoma: is the location of the intracranial tumor important?. Cancer 1999; 86: 135-141
- 5 Marcus DM, Brooks SE, Leff G. et al. Trilateral retinoblastoma: insights into histogenesis and management. Surv Ophthalmol 1998; 43: 59-70
- 6 Jakobiec FA, Tso MO, Zimmerman LE. et al. Retinoblastoma and intracranial malignancy. Cancer 1977; 39: 2048-2058
- 7 Abu Laban D, Al-Hussaini M, AlJabari R. et al. Metastatic unilateral retinoblastoma to the controlateral orbital optic nerve presenting with optic disc edema. Ophthalmol J 2023; 8: 62-67
- 8 Raffa L, Carret AS, Hamel P. et al. Two Cases of Retinoblastoma Invading the Optic Nerve Sheath. J Pediatr Ophthalmol Strabismus 2016; 53: e51-e53
- 9 Schonfeld SJ, Kleinerman RA, Abramson DH. et al. Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. Br J Cancer 2021; 124: 1312-1319
- 10 Miller NR. Primary tumours of the optic nerve and its sheath. Eye (Lond) 2004; 18: 1026-1037